Ryan Ford
YOU?
Author Swipe
View article: Cyber Threat Intelligence for Hybrid Attacks: Leveraging LLMs and Data Spaces
Cyber Threat Intelligence for Hybrid Attacks: Leveraging LLMs and Data Spaces Open
Cyberattacks have emerged as a critical component of modern hybrid warfare. To effectively counter these hybrid threats, societies require rapid detection and response capabilities. Cyber Threat Intelligence (CTI) provides means to capture…
View article: The Association of Metabolic-associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis
The Association of Metabolic-associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis Open
Introduction. Metabolic-associated fatty liver disease (MAFLD) is a hepatic manifestation of metabolic syndrome (MS). MAFLD patients have a higher prevalence of COVID-19. MAFLD is also associated with worse clinical outcomes of COVID-19, s…
View article: Initial attendance and retention in adult healthcare as criteria for transition success among organ transplant recipients
Initial attendance and retention in adult healthcare as criteria for transition success among organ transplant recipients Open
Background Adolescent and young adult (AYA) solid organ transplant recipients experience worsening medical outcomes during transition to adult healthcare. Current understanding and definitions of transition success emphasize first initiati…
View article: Hepatic Epithelioid Hemangioendothelioma Discovered Incidentally on Computerized Tomography
Hepatic Epithelioid Hemangioendothelioma Discovered Incidentally on Computerized Tomography Open
Hepatic epithelioid hemangioendothelioma (HEHE) is an exceedingly rare vascular tumor first described by Weiss and Enzinger in 1982.1 It is a neoplasm that can arise in many different parts of the body, but most frequently involves the liv…
View article: Treatment of <scp>HCV</scp> infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin
Treatment of <span>HCV</span> infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin Open
Summary Background Ledipasvir and sofosbuvir is a well‐tolerated regimen with high sustained virological response ( SVR ) rates in pre‐liver transplant patients infected with chronic hepatitis C virus ( HCV ), but data in liver transplant …